Future Pulse Cardiology

We would love to hear your thoughts on the episodes!

Dr. Elizabeth Ofili discusses the African American Heart Study with Dr. Thomas Nero.  They also discuss her work at the NIH and the African American Heart Failure Trial and the role of community based pragmatic clinical trials.

We would love to hear your thoughts on the episodes!

Dr. Thomas Nero discusses current therapy with Factor X inhibitors, the new research with Factor XI inhibition and specifically the enrolling Milvexian clinical trials with Dr. C Micahel Gibson.  In addition they discuss, the addition of these medications along wiht anti-platelet therapy, Lp(a) and other interesting current and future research in cardiovascular disease.

We would love to hear your thoughts on the episodes!

Dr. Thomas Nero speaks with Dr Peter Toth about the dramatic change occuring in diabtetes management and its effect on cardiovascular disease.  Starting with the biochemestry of diabetes and its effects at the cellular level, the discussion goes on to speak about the role SGLT2 inhibitors and GLP1 receptor agonists play in DM management as well as the future of diabetes care.  (If you want to skip the excelllent, but quite deep dive into biochemistry, jump to 11:22 - but honestly Dr. Toth's description is breathtaking)

We would love to hear your thoughts on the episodes!

Dr. Thomas Nero speaks with Dr. Peter Toth about the complex biology of lipids and atherosclerosis.  In this episode Dr Toth dives into LDL goals, therapies for attenuating non-LDL risk, vascular biology and the where are research studies lead us in choosing therapies.

We would love to hear your thoughts on the episodes!

Dr Paul Ridker discusses his paper on residual inflammatory risk that was recently published in the Lancet with Dr. Thomas Nero.  He discusses the pathology of inflammation as part of atherosclerosis, utilization of hs-CRP in clinical trials and in daily practice as well as current therapeutic options and ongoing investigations.

We would love to hear your thoughts on the episodes!

Dr Christopher Cannon discusses the potential of Pragmatic Clinical Trials in our research armamentarium with Dr. Thomas Nero.   They review the EVOLVE-MI trial for Early use of Evolocumab after Myocardial Infarction in detail and highlight the potential for future research.

We would love to hear your thoughts on the episodes!

Dr Sharoanne Hayes and Dr. Thomas Nero continue their discussion of SCAD focusing on genetics, trial design and the role of online registries as well as the holistic treatment of the SCAD patient.  This is part two of two.

We would love to hear your thoughts on the episodes!

Dr Sharonne Hayes of the May Clinic discusses SCAD with Dr. Thomas Nero.  Initially focusing on the new treatment paradigms, their wide ranging discussion covers etiology, pathophysiology and potential future therapeutic options.  Tis is the first of a two part podcast.

We would love to hear your thoughts on the episodes!

Dr. Nero discusses evaluation of  coronary artery disease and coronary inflammaiton with Dr. Cheerag Shirodaria from the University of Oxford.  Dr. Shirodaria along with Prof. Charalambos Antonidies at Caristo Diagnostics have developed a ground breaking technology that allows us to evaluate not just the severity of a coronary artery lesion, but also how inflamed it is and how likely it is to cause fatal and non-fatal myocardial infarction.  In addition, since it is a biologically active "marker" the Fat Attenuation Index (FAI) can also be used a a way to evaluate success of medical intervention.  Using computer post processing from standard 64 or 128 slice CT coronary angiography, they have been able to evaluate not just the vulnerable patient but also (possibly) the vulnerable plaque.

We would love to hear your thoughts on the episodes!

Prof. Christine Coughlin of Wake Forest School of Law speaks with Dr. Thomas Nero on the FDA approval process, emergency use authorization, Right to Try Legislation and the implications for clinical research, diversity and health care equity.  Prof. Coughlin holds positions in the College of Medicine as well as the Law school and in the Center for Bioethics.  She has published extensively on the FDA approval process.